MDR1 gene therapy - Genetix Pharmaceuticals

Drug Profile

MDR1 gene therapy - Genetix Pharmaceuticals

Latest Information Update: 08 Jul 2003

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Genetix Pharmaceuticals
  • Class Chemoprotectants; Gene therapies
  • Mechanism of Action P-glycoprotein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Chemotherapy-induced damage

Most Recent Events

  • 08 Jul 2003 Discontinued - Phase-I for Chemotherapy induced damage (Prevention)/Chemoprotection in USA (IV-infusion)
  • 07 Jan 2002 This programme is still in active development
  • 18 Feb 1998 Phase-I clinical trials for Chemotherapy induced damage (Prevention)/Chemoprotection in USA (IV-infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top